Skip to content

Open for responses

Request for Information – Prophylactic Platform for Medical Countermeasures

DEPT OF DEFENSE

Notice type
Special Notice
Solicitation #
W911SR27SPPFC
NAICS
541715
PSC
AC15
Set-aside
No Set aside used
Posted
October 19, 2026
Response due
November 18, 2026
Place of performance
Frederick, MD

What this opportunity is

The Department of Defense is seeking information from product developers for the Vaccine Acceleration by Modular Progression (VAMP) program, focused on creating prophylactic platform technologies for medical countermeasures against chemical, biological, radiological, and nuclear threats. This opportunity is open to all businesses, as there is no set-aside, and it is classified under NAICS 541715. Interested parties should note that this is a Special Notice, indicating that it is primarily for information gathering rather than a formal solicitation, which may require tracking for future bidding opportunities.

Analysis by Mindy, grounded in the SAM.gov notice.

Description

1 APPENDIX 2 PROJECT DESCRIPTION/STATEMENT OF OBJECTIVES PROJECT TITLE Vaccine Acceleration by Modular Progression (VAMP) - Prophylactic Platform Technology Medical Countermeasures (MCMs) Against Chemical, Biological, Radiological, and Nuclear (CBRN) Threats BACKGROUND/DESCRIPTION The Portfolio Management Executive for Chemical, Biological, Radiological, and Nuclear Defense (PME CBRND), Joint Program Manager – CBRN Medical (JPM-M) Accelerated Defense Pharmaceuticals (ADP) Product Office, is requesting from product developers the design, manufacture, non-clinical and clinical testing of advanced platform technology for prophylaxis against one or more specific CBRN threats of concern. The Government is interested in approaches that will support the development of prophylactic platform technology using traditional or non- traditional administration as well as immune modulating approaches. The VAMP program evaluates platform technologies against disease/injury caused by CBRN threats in appropriate animal models and human clinical trials for safety, immune response, and effectiveness while using data-driven decision and processes to bridge capability gaps for the warfighter. The goal of the program is to expedite the development of these prophylactic MCMs through a Phase I or Phase II clinical trial. To achieve this, the VAMP program utilizes a modular approach incorporating Go/No-Go checkpoints at each applicable non-clinical, clinical, CMC and regulatory phases to facilitate generation of an Investigational New Drug Application, end of Phase 1, or end of Phase 2 data packages supporting further advancement as warranted. As part of the current MCM environment to protect against CBRN threat agents listed in Appendix 1, the Government is interested in furthering the development of prototype candidates using either traditional (intramuscular injection) or alternative routes of administration (i.e., microneedles, intranasal, etc., and defined below as non-traditional administration). In addition, MCMs that can enhance and modulate the immune system (biological response modifiers) expand the Government’s toolbox of MCMs while building the warfighter’s bio-armor. To be eligible for funding, Offerors shall have a demonstrated, successful history of designing, manufacturing, and clinical testing of prophylactic MCM platform as well as experience working with the U.S. Food and Drug Administration (FDA). Additionally, Offerors will have expertise in all aspects of platform manufacturing under current Good Manufacturing Practices (cGMP) and prophylactic platform development with the intent to obtain licensure. Pending the outcome of program modules, the Government may consider further development and/or procurement of successful prophylaxes under a separate agreement. PROGRAM OBJECTIVES 1) Performance Objectives a. Program Objectives -- 1 of 8 -- 2 The project objectives include design, development, non-clinical testing, manufacturing and human clinical trials for mature prophylactic platform technologies. The project will result in successful prototype candidates that are safe to administer to humans to protect against Department of War (DoW) priority threats; work can be targeted to a threat or threats which could pivot and expand to other threat agents of interest upon a negotiated mutual modification. This includes complete product development and required stage-appropriate studies of these candidates against CBRN threats in Appendix 1. First-in-human products should include submission of an Investigational New Drug (IND), and all studies necessary through a Phase I clinical trial, as soon as possible. The prophylactic platform candidates, utilizing a traditional or non-traditional route of administration developed for this project, must target at least one of the CBRN threats of interest to the Government (preferably broad spectrum). Specifically, the Offeror is responsible for: Module 1: Design a prophylactic medical product candidate targeting one or more CBRN threats listed in Appendix 1. • Design a prophylactic medical product on manufacturable platform technology and formulate final candidate (prototype product) for clinical evaluation – This includes all methods and assays associated with the optimization, selection, and evaluation of an immunogenic platform construct, suitable for cGMP manufacture at development stage- appropriate levels, and human studies. • All aspects of construction and formulation of the platform candidate for delivery – Traditional delivery formulation methods/processes shall be supported by historical safety and immunogenicity data and align with selected mode of delivery. Non-traditional routes of administration shall be supported by technical testing and/or formulation for specific non-traditional route of administration, as applicable. • Acceptable modes of delivery include intramuscular injection and needle-free delivery (such as transdermal/microneedle skin patch, intranasal formulation, etc.). • Demonstrate established platform technology cGMP manufacturing, as needed. • Development of any lot release testing needed for cGMP production. • Stability testing of the prototype product to support human clinical use. Module 2: Animal studies, including toxicity and efficacy, as applicable. Initiated upon completion of prototype product design and formulation. • Perform pre-clinical studies to support submission of an IND in the effort for the prototype product. • Develop and establish stage-appropriate (i.e., qualified vs. validated) assays and methods suitable for intended use to measure the immunogenicity of the prototype product in humans and animals (i.e., non-human primates) demonstrated suitable for bridging animal efficacy outcomes to human clinical -- 2 of 8 -- 3 trial immunogenicity data. All immune assays to measure clinical endpoints are expected to be well-controlled (i.e., qualified or validated based on the phase of clinical study) prior to clinical…

Source: SAM.gov, as posted. Verify the current solicitation before responding.

Pursue this opportunity with Mindy

See who holds it now, who else is bidding, and draft your response — grounded in real government data, not generic AI.

View the original notice on SAM.gov ↗

Open opportunities in NAICS 541715